Page 1 of 93
MSN 625 Advanced Pharmacology Final Exam ACTUAL
Exam ALL 200 QUESTIONS AND CORRECT ANSWERS
LATEST UPDATE THIS YEAR
MSN 625: Advanced Pharmacology Final Exam Overview
This exam evaluates advanced clinical reasoning for Nurse Practitioners, focusing on high-risk
drug classes, life-span considerations (pediatrics/geriatrics), and evidence-based prescribing
guidelines.
• Core Pharmacokinetics: Half-life, steady state, first-pass effect, and cytochrome P450
(CYP) interactions.
• Cardiovascular: Hypertension (ACEI/ARB/CCB), Heart Failure (Entresto/Beta-blockers),
and Anticoagulation (DOACs).
• Endocrine: Diabetes management (GLP-1/SGLT2), Thyroid disorders, and Adrenal
insufficiency.
• Neurology/Psychiatry: Parkinson’s, Alzheimer’s, Seizures, SSRIs/SNRIs, and Atypical
Antipsychotics.
• Infectious Disease: Antibiotic selection, resistance mechanisms, and viral management
(HIV/Hepatitis).
• Respiratory: Asthma/COPD step-therapy and leukotriene modifiers.
MSN 625 Final Exam Questions 1–100 (Batch 1)
1. A 72-year-old patient with chronic kidney disease (CKD) requires a medication that is
primarily eliminated by the kidneys. Which change in pharmacokinetic parameters should the
provider anticipate most?
• A. Increased rate of hepatic metabolism via the CYP3A4 pathway.
1
, Page 2 of 93
• B. Significant decrease in the drug's half-life due to reduced clearance.
• C. Increase in the drug's steady-state concentration and risk of toxicity.
• D. Enhanced first-pass metabolism leading to lower bioavailability.
• Rationale: (C) Reduced renal clearance in CKD patients directly leads to drug
accumulation, increasing the steady-state plasma concentration. This necessitates lower
maintenance doses or longer dosing intervals to prevent systemic toxicity.
2. When prescribing a non-selective beta-blocker like Propranolol for a patient with essential
tremors, which comorbid condition is a relative contraindication for this therapy?
• A. Type 2 Diabetes Mellitus with frequent hypoglycemic episodes.
• B. Stage 1 Hypertension with a baseline heart rate of 88 bpm.
• C. Chronic stable angina requiring nitroglycerin supplementation.
• D. Benign Prostatic Hyperplasia (BPH) with urinary hesitancy.
• Rationale: (A) Non-selective beta-blockers can mask the autonomic symptoms of
hypoglycemia (e.g., tachycardia and tremors) and may inhibit gluconeogenesis, placing
diabetic patients at higher risk for unrecognized, severe low blood sugar.
3. A patient diagnosed with Heart Failure with Reduced Ejection Fraction (HFrEF) is being
switched from Lisinopril to Sacubitril/Valsartan (Entresto). What is the mandatory "washout"
period required before starting the new drug?
2
, Page 3 of 93
• A. No washout period is needed; the drugs can be switched immediately.
• B. 12 hours to ensure the ACE inhibitor is no longer active in the serum.
• C. 36 hours to minimize the risk of life-threatening angioedema.
• D. 7 days to allow the renal system to adjust to the change in afterload.
• Rationale: (C) Both ACE inhibitors and Neprilysin inhibitors (Sacubitril) increase
bradykinin levels. Concurrent use or inadequate washout periods significantly increase
the risk of angioedema. A 36-hour window is required by clinical guidelines.
4. A provider is considering starting a patient on Carbamazepine for trigeminal neuralgia.
Which genetic screening is recommended for patients of Asian descent prior to initiating
therapy?
• A. CYP2D6 ultra-rapid metabolizer phenotype.
• B. HLA-B*1502 allele to screen for Stevens-Johnson Syndrome risk.
• C. G6PD deficiency to prevent drug-induced hemolytic anemia.
• D. MTHFR gene mutation to assess for folate metabolism issues.
• Rationale: (B) The HLA-B*1502 allele is strongly associated with severe cutaneous
adverse reactions, including SJS and Toxic Epidermal Necrolysis, in Asian populations
taking Carbamazepine.
3
, Page 4 of 93
5. Which statement accurately describes the mechanism of action of SGLT2 inhibitors (e.g.,
Empagliflozin) in the management of Type 2 Diabetes?
• A. They increase insulin sensitivity by activating PPAR-gamma receptors.
• B. They inhibit the enzyme DPP-4 to increase levels of native incretins.
• C. They reduce glucose reabsorption in the proximal convoluted tubule of the kidney.
• D. They slow gastric emptying and increase satiety via the hypothalamus.
• Rationale: (C) SGLT2 inhibitors block the Sodium-Glucose Cotransporter 2, which is
responsible for most glucose reabsorption in the kidney. This results in glycosuria and
lower blood glucose levels, with secondary benefits in blood pressure and weight loss.
6. A 24-year-old female patient is prescribed Rifampin for the treatment of Latent
Tuberculosis. What critical education regarding oral contraceptives must the provider
provide?
• A. Rifampin increases the serum concentration of estrogen, causing spotting.
• B. rifampin induces CYP450 enzymes, significantly decreasing the efficacy of birth
control.
• C. rifampin inhibits estrogen metabolism, increasing the risk of thromboembolism.
• D. No interaction exists between Rifampin and hormonal contraceptives.
4
MSN 625 Advanced Pharmacology Final Exam ACTUAL
Exam ALL 200 QUESTIONS AND CORRECT ANSWERS
LATEST UPDATE THIS YEAR
MSN 625: Advanced Pharmacology Final Exam Overview
This exam evaluates advanced clinical reasoning for Nurse Practitioners, focusing on high-risk
drug classes, life-span considerations (pediatrics/geriatrics), and evidence-based prescribing
guidelines.
• Core Pharmacokinetics: Half-life, steady state, first-pass effect, and cytochrome P450
(CYP) interactions.
• Cardiovascular: Hypertension (ACEI/ARB/CCB), Heart Failure (Entresto/Beta-blockers),
and Anticoagulation (DOACs).
• Endocrine: Diabetes management (GLP-1/SGLT2), Thyroid disorders, and Adrenal
insufficiency.
• Neurology/Psychiatry: Parkinson’s, Alzheimer’s, Seizures, SSRIs/SNRIs, and Atypical
Antipsychotics.
• Infectious Disease: Antibiotic selection, resistance mechanisms, and viral management
(HIV/Hepatitis).
• Respiratory: Asthma/COPD step-therapy and leukotriene modifiers.
MSN 625 Final Exam Questions 1–100 (Batch 1)
1. A 72-year-old patient with chronic kidney disease (CKD) requires a medication that is
primarily eliminated by the kidneys. Which change in pharmacokinetic parameters should the
provider anticipate most?
• A. Increased rate of hepatic metabolism via the CYP3A4 pathway.
1
, Page 2 of 93
• B. Significant decrease in the drug's half-life due to reduced clearance.
• C. Increase in the drug's steady-state concentration and risk of toxicity.
• D. Enhanced first-pass metabolism leading to lower bioavailability.
• Rationale: (C) Reduced renal clearance in CKD patients directly leads to drug
accumulation, increasing the steady-state plasma concentration. This necessitates lower
maintenance doses or longer dosing intervals to prevent systemic toxicity.
2. When prescribing a non-selective beta-blocker like Propranolol for a patient with essential
tremors, which comorbid condition is a relative contraindication for this therapy?
• A. Type 2 Diabetes Mellitus with frequent hypoglycemic episodes.
• B. Stage 1 Hypertension with a baseline heart rate of 88 bpm.
• C. Chronic stable angina requiring nitroglycerin supplementation.
• D. Benign Prostatic Hyperplasia (BPH) with urinary hesitancy.
• Rationale: (A) Non-selective beta-blockers can mask the autonomic symptoms of
hypoglycemia (e.g., tachycardia and tremors) and may inhibit gluconeogenesis, placing
diabetic patients at higher risk for unrecognized, severe low blood sugar.
3. A patient diagnosed with Heart Failure with Reduced Ejection Fraction (HFrEF) is being
switched from Lisinopril to Sacubitril/Valsartan (Entresto). What is the mandatory "washout"
period required before starting the new drug?
2
, Page 3 of 93
• A. No washout period is needed; the drugs can be switched immediately.
• B. 12 hours to ensure the ACE inhibitor is no longer active in the serum.
• C. 36 hours to minimize the risk of life-threatening angioedema.
• D. 7 days to allow the renal system to adjust to the change in afterload.
• Rationale: (C) Both ACE inhibitors and Neprilysin inhibitors (Sacubitril) increase
bradykinin levels. Concurrent use or inadequate washout periods significantly increase
the risk of angioedema. A 36-hour window is required by clinical guidelines.
4. A provider is considering starting a patient on Carbamazepine for trigeminal neuralgia.
Which genetic screening is recommended for patients of Asian descent prior to initiating
therapy?
• A. CYP2D6 ultra-rapid metabolizer phenotype.
• B. HLA-B*1502 allele to screen for Stevens-Johnson Syndrome risk.
• C. G6PD deficiency to prevent drug-induced hemolytic anemia.
• D. MTHFR gene mutation to assess for folate metabolism issues.
• Rationale: (B) The HLA-B*1502 allele is strongly associated with severe cutaneous
adverse reactions, including SJS and Toxic Epidermal Necrolysis, in Asian populations
taking Carbamazepine.
3
, Page 4 of 93
5. Which statement accurately describes the mechanism of action of SGLT2 inhibitors (e.g.,
Empagliflozin) in the management of Type 2 Diabetes?
• A. They increase insulin sensitivity by activating PPAR-gamma receptors.
• B. They inhibit the enzyme DPP-4 to increase levels of native incretins.
• C. They reduce glucose reabsorption in the proximal convoluted tubule of the kidney.
• D. They slow gastric emptying and increase satiety via the hypothalamus.
• Rationale: (C) SGLT2 inhibitors block the Sodium-Glucose Cotransporter 2, which is
responsible for most glucose reabsorption in the kidney. This results in glycosuria and
lower blood glucose levels, with secondary benefits in blood pressure and weight loss.
6. A 24-year-old female patient is prescribed Rifampin for the treatment of Latent
Tuberculosis. What critical education regarding oral contraceptives must the provider
provide?
• A. Rifampin increases the serum concentration of estrogen, causing spotting.
• B. rifampin induces CYP450 enzymes, significantly decreasing the efficacy of birth
control.
• C. rifampin inhibits estrogen metabolism, increasing the risk of thromboembolism.
• D. No interaction exists between Rifampin and hormonal contraceptives.
4
